WO2021000968A3 - 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 - Google Patents

一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 Download PDF

Info

Publication number
WO2021000968A3
WO2021000968A3 PCT/CN2020/110085 CN2020110085W WO2021000968A3 WO 2021000968 A3 WO2021000968 A3 WO 2021000968A3 CN 2020110085 W CN2020110085 W CN 2020110085W WO 2021000968 A3 WO2021000968 A3 WO 2021000968A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
infection
adenovirus carrier
vaccine used
sars
Prior art date
Application number
PCT/CN2020/110085
Other languages
English (en)
French (fr)
Other versions
WO2021000968A2 (zh
Inventor
陈凌
关素华
杨臣臣
刘晓琳
Original Assignee
广州恩宝生物医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010110070.8A external-priority patent/CN110951756B/zh
Priority claimed from CN202010145657.2A external-priority patent/CN110974950B/zh
Application filed by 广州恩宝生物医药科技有限公司 filed Critical 广州恩宝生物医药科技有限公司
Priority to EP20829299.5A priority Critical patent/EP3804751A4/en
Priority to US17/260,820 priority patent/US20210283244A1/en
Priority to PH12021550029A priority patent/PH12021550029A1/en
Publication of WO2021000968A2 publication Critical patent/WO2021000968A2/zh
Publication of WO2021000968A3 publication Critical patent/WO2021000968A3/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明公开了一种用于预防SARS-CoV-2感染的腺病毒载体疫苗，所述疫苗包括如SEQ ID NO：1所示的核苷酸序列。本发明一些实例的疫苗，其含有的S蛋白核苷酸序列易于在人体细胞表达，可以诱导产生S蛋白，有望作为一种重组病毒疫苗，用于预防SARS-CoV-2感染。
PCT/CN2020/110085 2020-02-23 2020-08-19 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 WO2021000968A2 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP20829299.5A EP3804751A4 (en) 2020-02-23 2020-08-19 ADENOVIRUS CARRIER VACCINE FOR THE PREVENTION OF SARS-COV-2 INFECTION
US17/260,820 US20210283244A1 (en) 2020-02-23 2020-08-19 Adenovirus-vectored vaccine for preventing sars-cov-2 infection
PH12021550029A PH12021550029A1 (en) 2020-02-23 2021-01-04 Adenovirus-vectored vaccine for preventing sars-cov-2 infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010110070.8A CN110951756B (zh) 2020-02-23 2020-02-23 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN202010110070.8 2020-02-23
CN202010145657.2A CN110974950B (zh) 2020-03-05 2020-03-05 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
CN202010145657.2 2020-03-05

Publications (2)

Publication Number Publication Date
WO2021000968A2 WO2021000968A2 (zh) 2021-01-07
WO2021000968A3 true WO2021000968A3 (zh) 2021-02-18

Family

ID=74100237

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2020/110086 WO2021000969A2 (zh) 2020-02-23 2020-08-19 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
PCT/CN2020/110085 WO2021000968A2 (zh) 2020-02-23 2020-08-19 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/110086 WO2021000969A2 (zh) 2020-02-23 2020-08-19 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用

Country Status (4)

Country Link
US (2) US20220347289A1 (zh)
EP (2) EP3804751A4 (zh)
PH (2) PH12021550029A1 (zh)
WO (2) WO2021000969A2 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
EP3922263A4 (en) * 2020-03-16 2022-06-29 Guangzhou N Biomed Ltd. Ad7 vector vaccine for preventing sars-cov-2 infection
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
AU2021405281A1 (en) 2020-12-22 2023-07-06 CureVac SE Rna vaccine against sars-cov-2 variants
CN112679605B (zh) * 2021-03-15 2021-07-09 安源医药科技（上海）有限公司 针对新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用
WO2023002492A1 (en) * 2021-07-22 2023-01-26 Yeda Research And Development Co. Ltd. Codon optimization of nucleic acids
CN114150005B (zh) * 2022-02-09 2022-04-22 广州恩宝生物医药科技有限公司 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091524A2 (en) * 2003-04-14 2004-10-28 Acambis Inc. Respiratory virus vaccines
CN1572875A (zh) * 2003-06-17 2005-02-02 深圳市清华源兴生物医药科技有限公司 抗sars疫苗
US20080267992A1 (en) * 2004-06-04 2008-10-30 Cancer Center, Sun Yat-Sun University Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine
CN105273067A (zh) * 2015-03-13 2016-01-27 中国疾病预防控制中心病毒病预防控制所 一种编码MERS-CoV棘突蛋白的重组41型腺病毒载体疫苗
WO2016116398A1 (en) * 2015-01-19 2016-07-28 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (mers-cov)
CN110951756A (zh) * 2020-02-23 2020-04-03 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN110974950A (zh) * 2020-03-05 2020-04-10 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1276777C (zh) * 2003-05-21 2006-09-27 中山大学肿瘤防治中心 腺病毒载体sars疫苗及其制备方法，冠状病毒s基因的应用
CN1570115A (zh) * 2003-07-16 2005-01-26 陈克勤 优化的sars冠状病毒刺突蛋白基因
US7396914B2 (en) * 2003-08-04 2008-07-08 University Of Massachusetts SARS nucleic acids, proteins, antibodies, and uses thereof
CA2553541C (en) * 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
CN111821433B (zh) * 2020-02-06 2021-06-08 深圳市瑞吉生物科技有限公司 mRNA疫苗及其合成方法、试剂盒

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091524A2 (en) * 2003-04-14 2004-10-28 Acambis Inc. Respiratory virus vaccines
CN1572875A (zh) * 2003-06-17 2005-02-02 深圳市清华源兴生物医药科技有限公司 抗sars疫苗
US20080267992A1 (en) * 2004-06-04 2008-10-30 Cancer Center, Sun Yat-Sun University Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine
WO2016116398A1 (en) * 2015-01-19 2016-07-28 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (mers-cov)
CN105273067A (zh) * 2015-03-13 2016-01-27 中国疾病预防控制中心病毒病预防控制所 一种编码MERS-CoV棘突蛋白的重组41型腺病毒载体疫苗
CN110951756A (zh) * 2020-02-23 2020-04-03 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN110974950A (zh) * 2020-03-05 2020-04-10 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗

Also Published As

Publication number Publication date
EP3805392A4 (en) 2022-06-29
EP3804751A2 (en) 2021-04-14
WO2021000969A2 (zh) 2021-01-07
WO2021000969A3 (zh) 2021-02-18
US20210283244A1 (en) 2021-09-16
WO2021000968A2 (zh) 2021-01-07
PH12021550029A1 (en) 2021-09-27
EP3804751A4 (en) 2022-04-27
US20220347289A1 (en) 2022-11-03
EP3805392A2 (en) 2021-04-14
PH12021550030A1 (en) 2021-09-20

Similar Documents

Publication Publication Date Title
WO2021000968A3 (zh) 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
JP2019527055A5 (zh)
DK33190D0 (da) Hiv-3 retrovirus og anvendelse heraf
MX2022010027A (es) Vacuna 2019-ncov (sars-cov-2).
WO2002022080A3 (en) Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
IL134830A0 (en) Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
MXPA02001223A (es) Proteinas derivadas del virus de sindrome de mancha blanca y usos de las mismas.
RU2006105498A (ru) Полипептиды для индукции защитного иммунного ответа против staphylococcus aureus
UA85371C2 (ru) Модифицированный вирус коровьей оспы ankara для вакцинации новорожденных
PH12020500239A1 (en) Factor viii (fviii) gene therapy methods
JP2010508030A5 (zh)
EP2390340A3 (en) vector encoding Papillomavirus E1 and E2 polypeptides with reduced percentage of identity
WO2019220403A3 (en) Stabilised superoxide dismutase (sod) homolog gene and uses thereof
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
HUP9801334A2 (hu) A 18-as típusú humán papillomavírust kódoló DNS
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
MX2022016287A (es) Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas.
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
WO2006109174A3 (en) Hiv vaccine comprising a glycoprotein 120 signal sequence with no more than one positively charged amino acid
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
WO2022146154A3 (en) Peptide for use in the treatment or prevention of covid-19
WO2023193025A3 (en) Novel peptides and vaccines capable of eliciting protective immunity against sars-cov-2
WO2022035860A3 (en) Replication-competent adenovirus type 4-hiv env vaccines and their use
DE60223232D1 (de) Mucinpeptid mit immunstärkenden eigenschaften
PL442478A1 (pl) Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020829299

Country of ref document: EP

Effective date: 20210111

WWE Wipo information: entry into national phase

Ref document number: 2101000978

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE